Connection

Co-Authors

This is a "connection" page, showing publications co-authored by ADEL K EL-NAGGAR and GUILLERMINA LOZANO.
Connection Strength

3.202
  1. p53R172H and p53R245W Hotspot Mutations Drive Distinct Transcriptomes in Mouse Mammary Tumors Through a Convergent Transcriptional Mediator. Cancer Res Commun. 2024 Aug 01; 4(8):1991-2007.
    View in: PubMed
    Score: 0.244
  2. Mutant p53 protects triple-negative breast adenocarcinomas from ferroptosis in vivo. Sci Adv. 2024 Feb 16; 10(7):eadk1835.
    View in: PubMed
    Score: 0.237
  3. Triple-negative breast tumors are dependent on mutant p53 for growth and survival. Proc Natl Acad Sci U S A. 2023 08 22; 120(34):e2308807120.
    View in: PubMed
    Score: 0.228
  4. Differential Gain-of-Function Activity of Three p53 Hotspot Mutants In Vivo. Cancer Res. 2022 05 16; 82(10):1926-1936.
    View in: PubMed
    Score: 0.210
  5. p73 gene alterations and expression in primary oral and laryngeal squamous carcinomas. Carcinogenesis. 2001 May; 22(5):729-35.
    View in: PubMed
    Score: 0.195
  6. Dicer1 Phosphomimetic Promotes Tumor Progression and Dissemination. Cancer Res. 2019 05 15; 79(10):2662-2668.
    View in: PubMed
    Score: 0.169
  7. Somatic Trp53 mutations differentially drive breast cancer and evolution of metastases. Nat Commun. 2018 09 27; 9(1):3953.
    View in: PubMed
    Score: 0.163
  8. Synergistic and additive effect of retinoic acid in circumventing resistance to p53 restoration. Proc Natl Acad Sci U S A. 2018 02 27; 115(9):2198-2203.
    View in: PubMed
    Score: 0.156
  9. Spatio-Temporal Genomic Heterogeneity, Phylogeny, and Metastatic Evolution in Salivary Adenoid Cystic Carcinoma. J Natl Cancer Inst. 2017 10 01; 109(10).
    View in: PubMed
    Score: 0.152
  10. Contrasting effects of an Mdm2 functional polymorphism on tumor phenotypes. Oncogene. 2018 01 18; 37(3):332-340.
    View in: PubMed
    Score: 0.152
  11. Novel MYBL1 Gene Rearrangements with Recurrent MYBL1-NFIB Fusions in Salivary Adenoid Cystic Carcinomas Lacking t(6;9) Translocations. Clin Cancer Res. 2016 Feb 01; 22(3):725-33.
    View in: PubMed
    Score: 0.134
  12. Pla2g16 phospholipase mediates gain-of-function activities of mutant p53. Proc Natl Acad Sci U S A. 2014 Jul 29; 111(30):11145-50.
    View in: PubMed
    Score: 0.122
  13. Therapeutic efficacy of p53 restoration in Mdm2-overexpressing tumors. Mol Cancer Res. 2014 Jun; 12(6):901-11.
    View in: PubMed
    Score: 0.119
  14. Multiple stress signals activate mutant p53 in vivo. Cancer Res. 2011 Dec 01; 71(23):7168-75.
    View in: PubMed
    Score: 0.100
  15. Differential gene expression profiling of aggressive and nonaggressive follicular carcinomas. Hum Pathol. 2011 Sep; 42(9):1213-20.
    View in: PubMed
    Score: 0.097
  16. Mdm2 and Mdm4 loss regulates distinct p53 activities. Mol Cancer Res. 2008 Jun; 6(6):947-54.
    View in: PubMed
    Score: 0.080
  17. High levels of the p53 inhibitor MDM4 in head and neck squamous carcinomas. Hum Pathol. 2007 Oct; 38(10):1553-62.
    View in: PubMed
    Score: 0.075
  18. Mammary tumor modifiers in BALB/cJ mice heterozygous for p53. Mamm Genome. 2007 May; 18(5):300-9.
    View in: PubMed
    Score: 0.074
  19. A genetic mouse model for metastatic lung cancer with gender differences in survival. Oncogene. 2007 Oct 18; 26(48):6896-904.
    View in: PubMed
    Score: 0.074
  20. p21 delays tumor onset by preservation of chromosomal stability. Proc Natl Acad Sci U S A. 2006 Dec 26; 103(52):19842-7.
    View in: PubMed
    Score: 0.072
  21. Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome. Cell. 2004 Dec 17; 119(6):861-72.
    View in: PubMed
    Score: 0.063
  22. Chromosome stability, in the absence of apoptosis, is critical for suppression of tumorigenesis in Trp53 mutant mice. Nat Genet. 2004 Jan; 36(1):63-8.
    View in: PubMed
    Score: 0.059
  23. An alternatively spliced HDM2 product increases p53 activity by inhibiting HDM2. Oncogene. 2001 Jul 05; 20(30):4041-9.
    View in: PubMed
    Score: 0.049
  24. High metastatic potential in mice inheriting a targeted p53 missense mutation. Proc Natl Acad Sci U S A. 2000 Apr 11; 97(8):4174-9.
    View in: PubMed
    Score: 0.045
  25. Mapping and mutational analysis of the human TAF2G gene encoding a p53 cofactor. Genomics. 1999 Apr 01; 57(1):182-3.
    View in: PubMed
    Score: 0.042
  26. Constitutive Dicer1 phosphorylation accelerates metabolism and aging in vivo. Proc Natl Acad Sci U S A. 2019 01 15; 116(3):960-969.
    View in: PubMed
    Score: 0.041
  27. p53-mediated senescence impairs the apoptotic response to chemotherapy and clinical outcome in breast cancer. Cancer Cell. 2012 Jun 12; 21(6):793-806.
    View in: PubMed
    Score: 0.026
  28. Restoring expression of wild-type p53 suppresses tumor growth but does not cause tumor regression in mice with a p53 missense mutation. J Clin Invest. 2011 Mar; 121(3):893-904.
    View in: PubMed
    Score: 0.024
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.